Our Governance

Our Governance

The Governance Committee plays a critical role in overseeing and guiding the strategic direction of FutureNeuro with input from Scientific, Industry and Data and Digital Health Advisory Committees and other appropriate international input and benchmarking.

Key responsibilities include:

• Providing strategic guidance and direction to ensure alignment with FutureNeuro’s mission and objectives.
• Evaluating the performance of FutureNeuro’s activities, leadership, and committees to drive continuous improvement.
• Facilitating collaboration and informed decision-making among committee members to achieve organizational goals.
• Representing FutureNeuro to external stakeholders, fostering relationships, and promoting engagement with the wider community.

Our Committee members collectively have a broad range of skills and experience including those affected by neurological conditions as well as healthcare professionals and experts from diverse scientific disciplines.

Scientific Advisory Committee

The Scientific Advisory Committee plays a pivotal role in steering the trajectory of FutureNeuro. Comprising a select group of leading international researchers from academia, industry, and relevant research organisations, the committee ensures our Leadership Team remains attuned to cutting-edge trends and developments. Their valuable feedback and ideas propel the Centre’s development, informing strategic decisions that shape the future of neurological research

Current membership includes: 

• Dr Nick Lench, Executive Director, MRC/UKRI Nucleic Acid Therapy. Bringing expertise in genomics, translational therapeutics and an industry perspective.​
• Prof Hermona Soreq, Professor of Molecular Neuroscience at The Hebrew University of Jerusalem. Bringing expertise in Non-coding RNAs, especially MicroRNAs.
• Prof Donato Di Monte, Professor and Senior Group Leader at German Centre for Neurodegenerative Diseases (DZNE). Bringing expertise in Parkinson’s and pathogenetic mechanisms that are triggered and modulated by risk factors, such as environmental challenges, gene-environment interactions and aging.
• Prof Jeff Noebels, Professor of Neurology, Neuroscience, and Molecular and Human Genetics, Baylor College of Medicine. Bringing clinical expertise in gene control of neuronal excitability, epilepsy.
• Dr Caroline Ingre, Head of the ALS Centre, Karolinska Institute. Bringing expertise in neuromuscular disease and clinical trials for ALS.
• Prof Belinda Lennox, Head of Dept of Psychiatry, University of Oxford. Bringing expertise in psychosis).​

Industry Advisory Committee

The Industry Advisory Committee actively contributes to shaping our research agenda and strategic direction. Comprising representatives from a diverse range of industry partners, this committee is a nexus of insights, incorporating voices from consultants, industry thought-leaders, the investment community, policy advisors and public and patient engagement representatives. Together, they help us to navigate the intersection of research, industry needs and societal impact.

Current membership includes:

• Prof David Henshall, (Chair), Director FutureNeuro Centre.
• Ms Gwynne Morley, General Manager, IQVIA Ireland.
• Dr Dara Meldrum, Trinity College Dublin.
• Dr Christopher Whelan, Director JnJ Innovative Medicine.
• Dr Chantelle Kiernan, Head of Innovation and R&D, IDA
• Dr Christian Wolff, Head of Epilepsy Discovery Research, UCB